Castlekeep Investment Advisors LLC Takes Position in Cencora, Inc. (NYSE:COR)

Castlekeep Investment Advisors LLC bought a new stake in shares of Cencora, Inc. (NYSE:COR - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 7,820 shares of the company's stock, valued at approximately $1,757,000.

Several other large investors have also recently modified their holdings of the stock. Whittier Trust Co. increased its position in Cencora by 0.6% during the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock valued at $1,765,000 after acquiring an additional 44 shares during the last quarter. Shepherd Financial Partners LLC grew its holdings in Cencora by 0.9% during the 4th quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company's stock valued at $1,223,000 after purchasing an additional 46 shares during the last quarter. WASHINGTON TRUST Co raised its position in Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after purchasing an additional 46 shares during the period. JFS Wealth Advisors LLC raised its position in Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after purchasing an additional 46 shares during the period. Finally, Cullen Frost Bankers Inc. lifted its stake in Cencora by 1.1% in the fourth quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company's stock worth $1,003,000 after purchasing an additional 47 shares during the last quarter. Institutional investors own 97.52% of the company's stock.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 14,579 shares of the stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the completion of the sale, the chairman now owns 315,913 shares of the company's stock, valued at $89,027,442.53. This represents a 4.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Robert P. Mauch sold 4,970 shares of Cencora stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the transaction, the chief executive officer now directly owns 51,070 shares in the company, valued at $13,022,850. This represents a 8.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 45,223 shares of company stock valued at $12,369,767. Corporate insiders own 10.80% of the company's stock.

Cencora Stock Up 0.3%

Cencora stock traded up $0.89 during midday trading on Thursday, hitting $290.08. 347,358 shares of the company's stock were exchanged, compared to its average volume of 1,538,719. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The company has a market cap of $56.22 billion, a PE ratio of 41.26, a P/E/G ratio of 1.31 and a beta of 0.60. The firm has a 50-day moving average of $283.90 and a two-hundred day moving average of $257.97. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $309.35.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. The firm had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The company's quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm earned $3.80 earnings per share. As a group, analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 2nd. Stockholders of record on Friday, May 16th will be given a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.76%. The ex-dividend date of this dividend is Friday, May 16th. Cencora's payout ratio is 25.52%.

Analysts Set New Price Targets

A number of research analysts have recently commented on COR shares. Bank of America upped their target price on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Wall Street Zen raised Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. UBS Group increased their target price on Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Wells Fargo & Company boosted their target price on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research note on Friday, March 14th. Finally, Citigroup upped their price target on shares of Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $301.18.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.